PharmaPoint: Alzheimer’s Disease – Global Drug Forecast and Market Analysis to 2026

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Alzheimer’s disease (AD) is a progressive neurodegenerative disease that is characterized by impaired memory and thinking (known as dementia), and functional decline. With a rapidly accelerating worldwide prevalence, there is a growing societal pressure for curative treatment for AD patients. The burden of AD encompasses clinical burden to patients as well as economic burden to payers and patients and caregiver burden, adding to the urgent need for improved AD therapy. Significant efforts are being made to develop a new treatment for AD, as current pharmacologic management is known to only provide a temporary improvement in symptoms.
 
GlobalData estimates the 2016 sales for AD at approximately $3.0B across the 7MM covered in this report.

The AD pipeline activity is strong, with twenty active Phase III (or Phase II/III) pipeline agents, most notable drug classes of which being passive immunotherapies and BACE inhibitors. These late-phase drugs also include those targeted for AD-linked agitation and cognitive impairments. Despite the fierce competition, GlobalData expects AD drug development to continue to see considerable struggles until reliable biomarkers and diagnostics are developed. Nevertheless, the treatment landscape of AD is expected to see a substantial change during the forecast period of 2016-2026.

Scope

Overview of AD: including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

Annualized AD market revenue, cost of therapy per patient, and treatment usage patterns in three patient segments (including mild cognitive impairment, mild AD, moderate AD, and severe AD), forecast from 2016 to 2026.

Key topics covered: strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the AD therapeutics market

Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for AD therapy. The most promising candidate in Phase III (and Phase II/III) development is profiled.

Analysis of the current and future market competition in the global AD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global AD therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AD therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

AB Science
Abbvie
AC Immune
Acadia
Actinogen Medical
Adamas Pharmaceuticals
Allergan
Amgen
Archer Pharmaceuticals
AstraZeneca
Ausio Pharmaceuticals
Axovant
AZ Therapies
BioArctic NeuroScience AB
Biogen
Biogen
Bionomics
Boehringer Ingelheim
Boehringer Ingelheim
Bristol-Myers Squibb
Charsire Biotechnology Corp
Chugai
Cytos Biotechnology
Daiichi Sankyo
Eisai
Eli Lilly
Enzymotec
Glovia Co
Grifols
ImmunoBrain
Checkppoint
IntraCellular Therapies
Ionis
Janssen
Kyowa Hakko Kirin
Ligand
Lundbeck
Lupin
Mediti Pharma Inc
Merck & Co
Merz
Metabolic Therapy Inc
MorphoSys
Nature Cell
Nature Cell
Neurim Pharmaceuticals
Neurimmune
Neurotrope BioScience
Novartis
Ono Pharmaceutical
Orion Oyj
Otsuka
Pfizer
PharmatrophiX
Probiodrug AG
Proclara Biosciences
Purdue Pharma
QR Pharm
QR Pharma
Roche
Shionogi
Suven Life Sciences
T3D Therapeutics
Takeda
TauRx
Tetra Discovery Partners
Toyama Chemical
vTv Therapeutics
Zinfandel

Table of Contents

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Executive Summary

2.1 Alzheimer’s Market Forecast to See Double-Digit Sales Growth out to 2026

2.2 Allergan, Biogen, and Roche Are Forecast to Lead the AD Market in 2026

2.3 Lack of Treatments and Biomarkers Remain As Key Unmet Needs in the AD Market

2.4 Opportunities Remain for Disease-Modifying and Symptomatic Drugs Entering the AD Market

2.5 Twenty Promising Drugs in Phase II/III or Phase III of Development

2.6 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Etiology

4.1.2 Pathophysiology

4.2 Disease Staging Systems

4.3 Symptoms

4.4 Prognosis

4.5 Quality of Life

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.4.1 Sources

5.4.2 Forecast Assumptions and Methods

5.4.3 Total Prevalent Cases of AD

5.4.4 Total Prevalent Cases of AD by Severity

5.4.5 Total Prevalent Cases of MCI

5.5 Epidemiological Forecast for AD (2016–2026)

5.5.1 Total Prevalent Cases of AD

5.5.2 Age-Specific Total Prevalent Cases of AD

5.5.3 Sex-Specific Total Prevalent Cases of AD

5.5.4 Total Prevalent Cases of AD by Severity

5.6 Epidemiological Forecast for MCI (2016–2026)

5.6.1 Total Prevalent Cases of MCI

5.6.2 Age-Specific Total Prevalent Cases of MCI

5.6.3 Sex-Specific Total Prevalent Cases of MCI

5.7 Discussion

5.7.1 Epidemiological Forecast Insight

5.7.2 Limitations of Analysis

5.7.3 Strengths of Analysis

6 Disease Management

6.1 Diagnosis Overview

6.1.1 Probable AD Dementia

6.1.2 Preclinical AD

6.1.3 MCI

6.2 Treatment Overview

6.3 Clinical Practice

6.3.1 Leading Prescribed Therapies

6.4 US

6.5 5EU

6.6 Japan

7 Competitive Assessment

7.1 Overview

7.2 Product Profiles – Major Brands

7.2.1 Aricept (Donepezil Hydrochloride)

7.2.2 Exelon (Rivastigmine, Rivastigmine tartrate)

7.2.3 Razadyne (Galantamine Hydrobromide)

7.2.4 Namenda (Memantine Hydrochloride)

7.2.5 Namzaric (Memantine and Donepezil Hydrochlorides)

7.3 Other Therapeutic Classes

8 Unmet Needs and Opportunity Assessment

8.1 Overview

8.2 Drugs with Disease-Modifying Mechanisms of Action

8.2.1 Unmet Need

8.2.2 Gap Analysis

8.2.3 Opportunity

8.3 Diagnosis in the Prodromal or Presymptomatic Stages

8.3.1 Unmet Need

8.3.2 Gap Analysis

8.3.3 Opportunity

8.4 Improved Control of Symptoms

8.4.1 Unmet Need

8.4.2 Gap Analysis

8.4.3 Opportunity

8.5 Easier Access to Treatment

8.5.1 Unmet Need

8.5.2 Gap Analysis

8.5.3 Opportunity

9 Pipeline Assessment

9.1 Overview

9.2 Clinical Trial Mapping

9.2.1 Clinical Trials by Class

9.3 Promising Drugs in Clinical Development

9.3.1 Biopharmaceutical Products

9.3.2 Gantenerumab

9.3.3 Crenezumab

9.3.4 Aducanumab

9.3.5 Flebogamma + Albutein

9.3.6 CAD106

9.3.7 Small Molecule

9.3.8 Verubecestat

9.3.9 Elenbecestat

9.3.10 Lanabecestat

9.3.11 JNJ-54861911

9.3.12 CNP520

9.3.13 Azeliragon

9.3.14 Pioglitazone

9.3.15 Nilvadipine

9.3.16 Intepirdine

9.3.17 ALZT-OP1

9.3.18 TRx-0237 (LMTX)

9.3.19 Brexipiprazole

9.3.20 Aripiprazole

9.3.21 AVP-786

9.3.22 ITI-007

9.3.23 Other Drugs in Development

10 Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 Company Profiles

10.3.1 Allergan

10.3.2 Lundbeck

10.3.3 Eisai

10.3.4 Pfizer

10.3.5 Novartis

10.3.6 Roche

10.3.7 Biogen

10.3.8 Eli lilly

10.3.9 Merck & Co.

10.3.10 AstraZeneca

10.3.11 Takeda

11 Market Outlook

11.1 Global Markets

11.1.1 Forecast

11.1.2 Drivers and Barriers – Global Issues

11.2 US

11.2.1 Forecast

11.2.2 Key Events

11.2.3 Drivers and Barriers

11.3 5EU

11.3.1 Forecast

11.3.2 Key Events

11.3.3 Drivers and Barriers

11.4 Japan

11.4.1 Forecast

11.4.2 Key Events

11.4.3 Drivers and Barriers

12 Appendix

12.1 Bibliography

12.2 Abbreviations

12.3 Methodology

12.3.1 Forecasting Methodology

12.3.2 Diagnosed Patients

12.3.3 Percent Drug-Treated Patients

12.3.4 Drugs Included in Each Therapeutic Class

12.3.5 Launch and Patent Expiry Dates

12.3.6 General Pricing Assumptions

12.3.7 Individual Drug Assumptions

12.3.8 Generic Erosion

12.3.9 Pricing of Pipeline Agents

12.4 Primary Research – KOLs Interviewed for This Report

12.4.1 KOLs

12.4.2 Payers

12.5 Primary Research – Prescriber Survey

12.6 About the Authors

12.6.1 Analyst

12.6.2 Therapy Area Director

12.6.3 Epidemiologist

12.6.4 Managing Epidemiologist

12.6.5 Global Director of Therapy Analysis and Epidemiology

12.6.6 Global Head and EVP of Healthcare Operations and Strategy

12.7 About GlobalData

12.8 Contact Us

12.9 Disclaime

Frequently asked questions

PharmaPoint: Alzheimer’s Disease – Global Drug Forecast and Market Analysis to 2026 thematic reports
Currency USD
$10,995

Can be used by individual purchaser only

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

PharmaPoint: Alzheimer’s Disease – Global Drug Forecast and Market Analysis to 2026 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Pharmaceuticals
New
Immuno-oncology in pharma: neoepitope prediction
$250 | December 2023
Pharmaceuticals
New
Innovation in pharma: transdermal drug delivery
$250 | November 2023
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at PharmaPoint: Alzheimer’s Disease – Global Drug Forecast and Market Analysis to 2026 in real time.

  • Access a live PharmaPoint: Alzheimer’s Disease – Global Drug Forecast and Market Analysis to 2026 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.